作者
Keith S Kaye, Louis B Rice, Aaron L Dane, Viktor Stus, Olexiy Sagan, Elena Fedosiuk, Anita F Das, David Skarinsky, Paul B Eckburg, Evelyn J Ellis-Grosse
发表日期
2019/11/27
期刊
Clinical Infectious Diseases
卷号
69
期号
12
页码范围
2045-2056
出版商
Oxford University Press
简介
Background
ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States.
Methods
Hospitalized adults with suspected or microbiologically confirmed cUTI/AP were randomized 1:1 to 6 g ZTI-01 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch); patients with concomitant bacteremia could receive up to 14 days.
Results
Of 465 randomized patients, 233 and 231 were treated with ZTI-01 and PIP-TAZ, respectively. In the microbiologic modified intent-to-treat (m-MITT …
学术搜索中的文章
KS Kaye, LB Rice, AL Dane, V Stus, O Sagan… - Clinical Infectious Diseases, 2019